New Haven, CTNCT06884618Now EnrollingIRB Ready

Neoplasms Clinical Trial in New Haven, CT

Access cutting-edge neoplasms treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.

Sponsored by Hoffmann-La Roche

Quick Self-Assessment

See if you qualify for this New Haven location

Preparing your pre-screening questions…

Expert Care in New Haven

Access neoplasms specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related neoplasms treatment provided free

Apply for This New Haven Location

Check if you qualify for this neoplasms clinical trial in New Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Haven site if eligible
  4. 4Begin participation

About This Neoplasms Study in New Haven

This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and of other doses of interest for future development in selected solid tumor indications.

Sponsor: Hoffmann-La Roche

Who Can Participate

Inclusion Criteria

Histologically documented, locally advanced, recurrent, or metastatic incurable solid tumors
Participants with measurable disease according to RECIST v1.1 assessed by the investigator
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy ≥12 weeks
Adequate hematologic and end-organ function
Confirmed presence of the RAS mutation(s)

Exclusion Criteria

Current participant or enrollment in another interventional clinical trial
Known hypersensitivity or medical contraindication to any component of RO7673396 formulation
Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate study treatment absorption
Known and untreated, or active central nervous system (CNS) metastases
Participants with chronic diarrhea, short bowel syndrome or significant upper gastrointestinal (GI) surgery including gastric resection, a history of inflammatory bowel disease (IBD)
Treatment with chemotherapy, immunotherapy, biologic therapy, or an investigational agent as anti-cancer therapy within 4 weeks or five half-lives prior to initiation of study treatment
Participants who are on acid-reducing agents and unable to safely discontinue them as required in the study
Major surgical procedure within 28 days prior to initiation of study treatment, or incomplete recovery from surgery that would interfere with the determination of safety or efficacy of study treatment, or anticipation of need for a major surgical procedure during the study
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
Known clinically significant liver disease

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Haven?

Yes, this clinical trial (NCT06884618) has an active research site in New Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Neoplasms Treatment Options in New Haven, CT

If you're searching for neoplasms treatment options in New Haven, CT, this clinical trial (NCT06884618) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all neoplasms clinical trials near you to find additional studies recruiting in your area.

More Myeloproliferative Neoplasms Trials in New Haven, CT

See all myeloproliferative neoplasms clinical trials recruiting in New Haven — not just this study.

Browse Myeloproliferative Neoplasms Trials in New Haven →

Browse More Trials by Condition

Myeloproliferative Neoplasms TrialsMultiple Sclerosis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in New Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Haven, CT